microRNAs in liver and kidney ischemia reperfusion injury: insight to improve transplantation outcome

[Display omitted] •Ischemia reperfusion injury (IRI) is often associated with microvascular dysfunction.•Production and release of inflammatory mediators in IRI leads to tissue damage, especially during organ transplantation.•MicroRNAs (miRs) as genetic regulators, might attenuate or ameliorate this status.•Nowadays miRs has potential to be used as biomarkers and therapeutic agents. Ischemia reperfusion injury (IRI) is a condition that occurs wherever blood flow and oxygen is reduced or absent, such as trauma, vascular disease, stroke, and solid organ transplantation. This condition can lead to tissue damage, especially during organ transplantation. Under such circumstances, some signaling pathways are activated, leading to up- or down- regulation of several genes such as microRNAs (miRNAs) that might attenuate or ameliorate this status. Therefore, by manipulating miRNAs level, they can be used as a biomarker for early diagnosis of IRI or suggestive to be therapeutic agents in clinical situation in future.